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A B S T R A C T  
Objective: To determine the frequency of common chromosomal aberrations in local population of idiopathic 
acquired aplastic anemia at the time of diagnosis, using G-banding cytogenetic analysis. 
Patients and Methods: This cross sectional study was conducted in Department of Haematology, Pakistan 
Institute of Medical Sciences, and Islamabad and Department of Genetics, Children Hospital, Lahore from 
June 2015 to July 2017. Sample size was calculated using WHO sample size calculator. A total of sixty cases 
of peripheral blood pancytopenia having clinical suspicion of acquired aplastic anemia and diagnosed on bone 
marrow examination with aplastic anemia were included in the study. Bone marrow or peripheral blood 
samples were also processed for cytogenetics by G-banding and karyotyping according to International 
System for Human Cytogenetic Nomenclature (ISCN) to determine frequency of chromosomal abnormalities in 
the patients of acquired aplastic anaemia. 
Results: Sixty cases diagnosed to have acquired aplastic anaemia using bone marrow examination as gold 
standard were included in the study based on inclusion criteria. Forty-five out of 60 patients (75%) had 
successful karyotyping whereas 15 out of 60 patients (25%) had inconclusive cytogenetics due to culture 
failure, inadequate metaphase cells and contamination. G-banding revealed normal karyotyping in 40 out of 45 
patients (88.9%) while 5 out of 45 patients (11.1%) were found to have abnormal karyotyping. Chromosomal 
abnormalities revealed by abnormal karyotyping included three numerical abnormalities i.e. monosomy 7, 
trisomy 8, trisomy 14 and two structural abnormalities i.e. deletion of 11q, deletion of 13q. The frequency of 
chromosomal abnormalities in patients with acquired aplastic anaemia in this study was found to be 11.1%. 
Conclusion: Cytogenetic analysis may be beneficial in differentiating acquired AA from other haemopoietic 
disorders of bone marrow failure, which may be missed, based on cell morphology alone. It also guides in 
deciding appropriate mode of treatment earlier and predicting prognosis of the disease. 
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I n t r o d u c t i o n  
 
Aplastic anaemia is an immune mediated haemopoietic 
stem cell disorder characterized by pancytopenia with a 
hypocellular bone marrow in the absence of abnormal 
infiltrate and no increase in bone marrow reticulin.1  
Aplastic anemia is considered if at least two of the 
following defining criteria are fulfilled that includes 
haemoglobin level less than 10g/dl, neutrophil count less 
than 1.5 x 109/L, platelet count less than 50 x 109/L and 
bone marrow cellularity less than 25% or 25 to 50% with 
less than 30% residual haemopoietic cells.2 Disease 
severity of aplastic anemia is based on the criteria given 
by Camitta et al. in 1975.3 According to these criteria the 
severity of aplastic anemia is graded into very severe 
aplastic anaemia (VSAA), severe aplastic anemia (SAA) 
and non-severe aplastic anemia (NSAA). Severity of 
aplastic anaemia according Camitta criteria is based on 
blood cell counts and bone marrow cellularity.4 Grading of 
disease is significant in management decisions but has 
less prognostic value in terms of response to 
immunosuppressive therapy.5 
Incidence of aplastic anaemia in West is around 2 per 
million populations in a year, that is twofold higher (3 to 4 
per million population) in Asia.6 Aplastic anaemia can be 
congenital or acquired. 7 Presence of somatic 
abnormalities and characteristic sensitivity of 
haemopoietic cells to chromosomal breakage on 
exposure to clastogenic agents such as diepoxybutane 
(DEB) and mitomycin c (MMC) is suggestive of congenital 
aplastic anemia. 8 Some cases of congenital aplastic 
anemia may lack the characteristic phenotypic 
abnormalities.9 Constitutional mutations result in 
increased genomic instability and reduced cell survival in 
congenital aplastic anaemia that leads to increased 
chromosomal DNA damage by DNA crosslinking agents 
due to aberration in BRCA pathway.10  BRCA gene (a 
tumor suppressor gene) is involved in DNA damage 
response pathway; cells lacking BRCA protein are 
susceptible to chromosomal breakage after exposure to 
DEB or MMC.11 Acquired aplastic anaemia is associated 
with various etiological factors that include different drugs, 
chemicals, ionizing radiations, pregnancy, autoimmune 
diseases, graft versus host disease and viral infections.12 
No definitive causative factor is found in majority of the 
cases of acquired aplastic anaemia.13 Various drugs, 
chemicals, viral infections such as Hepatitis virus, 
Varicella Virus, Parvo virus, CMV, EBV, HIV and other 
factors such as Ionizing radiations, Smoking, Graft versus 
host disease etc. are associated with aplastic anemia.   
Cytogenetic abnormalities have been described 
infrequently worldwide in few patients (12%) with 
otherwise typical aplastic anaemia at diagnosis.14  
Common cytogenetic abnormalities related with idiopathic 
acquired aplastic anaemia include trisomy 6, trisomy 8, 
trisomy 14, trisomy 15, monosomy 7, monosomy 19, del 
5q and del 7q.15 
 
Figure 1: G-Banding Chromosomal analysis of 
peripheral blood cell culture reveals male 
karyotypewith a missing chromosome no.7 in 20 
metaphase cells examined. This finding is consistent 
with diagnosis of Monosomy 7 
 
 
Figure 2: G-Banding Chromosomal analysis of bone 
marrow cell culture reveals female karyotype with an 
extra chromosome no.8 in 20 metaphase cells 
examined. This finding is consistent with diagnosis of 
Trisomy 8 
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Monosomy 7 is associated with a high risk to develop 
haematological malignancies (MDS or AML) and has poor 
response to immunosuppressive therapy (IST) with poor 
prognosis.16  In contrast, trisomy 8 is associated with 
good response to IST and has better prognosis.17 
Cytogenetic analysis is attempted to detect cytogenetic 
abnormalities related with acquired aplastic anaemia, 
although it is difficult to perform because of inability to 
obtain sufficient metaphase cells for chromosomal 
analysis in a hypocellular bone marrow.18 In such 
situation, molecular cytogenetics by fluorescent in situ 
hybridization (FISH) can be attempted which is limited to 
few centers only and has a higher cost constraint. 19 
Clinical significance of cytogenetic abnormalities may also 
be that hypo plastic MDS or hypo plastic AML may 
present as aplastic anaemia and it can be difficult to 
distinguish two conditions on basis of morphology alone, 
treatment option and response to treatment is also 
different in such condition. 20  
Cytogenetic analysis is limited to a few centers in 
Pakistan. Incidence of aplastic anemia is relatively more 
common in Southeast Asian countries. No study has been 
conducted before, to find association of cytogenetic 
abnormalities with acquired AA in Pakistan. The objective 
of this study was to determine frequency of common 
chromosomal aberrations among the patients of idiopathic 
acquired aplastic anemia in local population at the time of 
diagnosis by G-banding cytogenetic analysis. 
 
Figure 3: G-Banding Chromosomal analysis of 
peripheral blood cell culture reveals female karyotype 
with an extra chromosome no.14 in 16 metaphase 
cells examined. This finding is consistent with 
diagnosis of Trisomy 14 
 
Figure 4: G-Banding chromosomal analysis of bone 
marrow cell culture reveals male karyotype with 
deletion of q-arm of chromosome no.11 in 16 
metaphase cells examined. (del 11q) 
 
Figure 5: G-Banding chromosomal analysis of 
peripheral blood cell culture reveals female karyotype 
with deletion of q-arm of chromosome no.13 in 16 
metaphase cells examined. (del 13q) 
P a t i e n t s  a n d  M e t h o d s  
This cross-sectional study was conducted in Department 
of Genetics, Department of Haematology, Children 
Hospital, Lahore and Department of Haematology, 
Pakistan Institute of Medical Sciences (PIMS), Islamabad 
from June 2015 to July 2017. In total 64 participants (both 
male and female patients of all age groups) who 
presented to the Department of Haematology with 
peripheral blood pancytopenia having a clinical suspicion 
of acquired aplastic anemia., with features of bone 
marrow aplasia were included in the study. Patients with 
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congenital aplastic anaemia, patients with features of 
bone marrow dysplasia and abnormal infiltrates and 
patients with post chemotherapy and radiotherapy aplasia 
were excluded from the study. The study was approved 
by ethical board of each participating hospital. Informed 
consent was taken from the patients or their parents. 
Sample size was calculated according to WHO sample 
size calculator with 95% confidence interval, prevalence 
of 12% cases of AA with chromosomal abnormalities and 
8% margin of error and sample size calculated was 60 
and sampling was done by convenient sampling 
technique. 
Demographic profile and clinical data of the patients was 
taken. Systemic examination was performed to find 
positive signs of anemia, haemorrhage, infections, 
lymphadenopathy, hepatomegaly, splenomegaly and 
especially any dysmorphic features to exclude congenital 
AA. Biochemical and radiological findings, CBC, 
reticulocyte count, peripheral blood smear and bone 
marrow (aspiration and trephine biopsy was done to 
confirm diagnosis of aplastic anemia Cytogenetics or 
chromosomal analysis was done by Giemsa Trypsin 
banding prior to induction of immunosuppressive therapy. 
Blood or Bone marrow samples were collected under 
aseptic measures in sterile sample collection tubes (green 
top vacutainers) containing sodium heparin anticoagulant 
to prevent coagulation. Samples were transported to 
genetics lab. at room temperature within 24 hours for 
cytogenetic analysis where they were processed for cell 
culture, culture harvesting, slide preparation and slide 
staining. Karyotyping was done according to (ISCN) 
International System for Human Cytogenetic 
Nomenclature21 metaphase and karyotype images were 
seen using cytovision system (microscope, camera, 
monitor, computer, software Macktype 5.6) for 
chromosome analysis. At least 16 to 20 metaphase cells 
were analyzed at each microscopic examination for a 
successful result. Cytogenetic analysis was labelled 
inconclusive if metaphase cells were less than 16. A 
cytogenetic abnormality was considered to exist when 2 
or more cells had the same structural or numerical 
chromosomal abnormality (86). Data was recorded and 
analyzed using Statistical Package for Social Sciences 
(SPSS) Version 20. Median was calculated for Age of the 
study participants and Frequency (%) of chromosomal 
abnormalities was calculated in the study patients 
diagnosed to have acquired aplastic anemia.  
R e s u l t s  
Four out of 64 cases were excluded from the study as per 
exclusion criteria, among those two cases (3.1%) were 
diagnosed to have Myelodysplastic syndrome based on 
peripheral blood and bone marrow findings while two 
cases (3.1%) were diagnosed as Congenital aplastic 
anemia on chromosomal breakage analysis. Sixty out of 
64 cases (93.8%) diagnosed to have acquired aplastic 
anemia on the basis of clinical, peripheral blood and bone 
marrow findings, were included in this study as per 
inclusion criteria. Diagnosis of aplastic anemia was 
confirmed by considering bone marrow findings as gold 
standard. Among 60 patients of acquired aplastic anemia, 
34 were male and 26 were female. Age distribution of the 
study participants ranged from 1 to 84 years with a 
median age of 10 years. Most of the study participants 
were children as 52 patients (81%) were in age group of 1 
- 18 years whereas 12 patients (19%) were in age group 
of 19 - 84 years.  
Forty five out of 60 patients (75%) had successful 
karyotyping among those 23 were male and 22 were 
female whereas 15 out of 60 patients (25%) had 
inconclusive cytogenetics.  
Table 1: Severity distribution of aplastic anemia 
among study patients 
Severity NSAA SAA VSAA 
Male 27 5 2 
Female 17 8 1 
Total 44 13 3 
Percentage 73.3% 21.7% 5% 
 
Table 2: Frequency breakup of Cytogenetics 
results among study patients 
Cytogenetics Normal Abnormal 
Male 24 2 
Female 16 3 
Total 40 5 
Percentage 89.9% 11.1% 
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Table 3: Categories of Chromosomal abnormalities 




 Trisomy 8 




 Deletion 13q 
 
Inconclusive cytogenetics can be due to cell culture 
failure, inadequate metaphase cells or contamination. G-
banding revealed normal cytogenetics results in 40 out of 
45 patients (89.9%) among those 24 were male and 16 
were female, while five out of 45 patients (11.1%) had 
cytogenetic abnormalities among those two were male 
and three were female, table 2. Majority of the patients of 
acquired aplastic anemia (n=40) included in this study 
had normal cytogenetics. In total 44 patients had NSAA, 
13 SAA and 3 patients had VSAA (Table 1). Among five 
patients with chromosomal abnormalities, three patients 
had severe aplastic anaemia (SAA) while two patients 
were diagnosed to have non-severe aplastic anaemia 
(NSAA).  Chromosomal abnormalities revealed by G-
banding in five patients of acquired aplastic anemia were 
numerical and structural. Three out of five patients had 
numerical chromosomal abnormalities among those one 
was male and two were female having monosomy 7, 
trisomy 8 and trisomy 14 respectively whereas two out of 
five patients had structural chromosomal abnormalities 
among those one was male and one was female having 
deletion of 11q and deletion of 13q respectively. All five 
patients of acquired aplastic anemia found to have 
abnormal cytogenetics in this study were in age group of 
1 - 18 years. The frequency breakup of chromosomal 
abnormalities is depicted in table 3. 
D i s c u s s i o n  
Aplastic anaemia is haematological disorder of bone 
marrow failure characterized by T cell mediated 
destruction of haemopoietic cells.22 In the current 
study, cytogenetic abnormalities were observed in 
11.1% patients of acquired aplastic anemia. Trisomy 
was the commonest numerical cytogenetic 
abnormality seen in two patients followed by 
monosomy in one patient. Deletions were the 
structural cytogenetic abnormalities found in two 
patients. Clinical and haematological profile of the 
patients with abnormal cytogenetics were similar to 
those with normal cytogenetics.23 Some of these 
characteristic cytogenetic abnormalities are also 
seen in myelodysplastic syndrome (MDS) and acute 
myeloid leukemia (AML), however the morphological 
diagnosis was consistent with aplastic anemia. It 
may be difficult to distinguish two conditions on the 
basis of cell morphology alone therefore in this 
situation abnormal karyotype may suggest diagnosis 
of hypoplastic MDS or hypoplastic AML. Cytogenetic 
analysis can play a significant role in management of 
patients with cytogenetic interpretation, which can 
reduce risk of misdiagnosing hypoplastic MDS and 
hypoplastic AML as aplastic anemia, monosomy and 
trisomy are mostly seen in aplastic anemia, deletions 
favor diagnosis of MDS whereas translocations and 
inversions are commonly found in AML. Cytogenetic 
analysis in this way may be most beneficial in 
differentiating aplastic anemia from other 
haemopoietic disorders of bone marrow 
hypoplasia/aplasia, therefore guides in suggesting 
appropriate mode of treatment that helps in avoiding 
possibility of mistreating the patients. Some 
authorities exclude diagnosis of aplastic anaemia in 
patients with abnormal cytogenetics regardless of 
bone marrow morphology, however in some 
research centers patients with abnormal cytogenetics 
are diagnosed as aplastic anemia on morphological 
grounds.24 Response to therapy and survival in 
patients of aplastic anaemia with normal and 
abnormal cytogenetics was also compared in some 
studies.25 Patients without cytogenetic abnormalities 
have good response to immunosuppressive therapy 
(IST) and better survival therefore cytogenetic 
analysis helps in predicting prognosis of aplastic 
anemia. Patients with persistent cytogenetic 
abnormalities after treatment are at higher risk of 
developing haematological malignancies (AML or 
MDS). Patients of MDS presents with clinical 
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manifestations of bone marrow failure which are 
related to anaemia, neutropenia and 
thrombocytopenia.26 Immunosuppressive therapy 
(IST) improves pancytopenia but response is 
relatively poor in patients of MDS.27  In few patients, 
acquired aplastic anaemia may develop into acute 
leukemia.28 Patients of AML presents with clinical 
features of bone marrow failure and organ infiltration 
by leukemic cells. Chemotherapy regimens have 
limited role in treating patients with AML.29  
In this study cytogenetic abnormalities in patients of 
acquired aplastic anemia were found to be 11.1% in 
our region. These findings are compatible with the 
study conducted by Vineeta Gupta et al. at Institute 
of Medical Sciences, Banaras University, India who 
found cytogenetic abnormalities to be 11.9% in 
patients of AA. 30   Similar figures are reported in 
various other studies, demonstrating chromosomal 
abnormalities in acquired AA.31  Some patients with 
acquired aplastic anaemia are at higher risk of 
evolving into MDS. It is sometimes difficult to 
distinguish between the two conditions.32  
Prognosis of the patients with acquired aplastic has 
improved with better supportive care of anaemia, 
infections and bleeding.33 Estimated 10-years 
survival is 68% in patients receiving IST and 73% in 
patients with HSCT. Mode of treatment in patients 
with aplastic anaemia depends on age of the 
patients, children with HLA matched sibling donor 
are preferably treated with HSCT whereas adults 
without HLA matched sibling donor are generally 
treated with IST along with supportive therapy. 
Approximately 25% patients of AA have inadequate 
response to therapy.34 HSCT is the curative 
treatment option, however may be at additional risk 
of developing graft versus host disease (GVHD) and 
potential for graft rejection.35. 
C o n c l u s i o n  
Cytogenetic analysis may be beneficial in 
differentiating acquired AA from other haemopoietic 
disorders of bone marrow failure, which may be 
missed, based on cell morphology alone. It also 
guides in deciding appropriate mode of treatment 
earlier and predicting prognosis of the disease. 
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